Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
- 1 February 2014
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 38 (2) , 236-242
Abstract
No abstract availableKeywords
Funding Information
- Regione Campania (DGRC 2362/07)
- MIUR (PS 35-126/Ind)
This publication has 29 references indexed in Scilit:
- Selective elimination of leukemia stem cells: Hitting a moving targetCancer Letters, 2013
- Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cellsProteomics, 2013
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2012
- Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual diseaseBlood, 2011
- SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemiaBlood, 2011
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJournal of Clinical Investigation, 2011
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialThe Lancet Oncology, 2010
- Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-AblCancer Cell, 2010
- International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.Blood, 2009